secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001193125-26-012664
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana: UP421 survives 12 months in T1D with no immunosuppression; plans SC451 IND, SG293 data in 2026
--------------------------------------------------------------------------------

- UP421, a hypoimmune pancreatic islet cell therapy, continued to survive and function at 12 months post-transplant in a T1D patient with no immunosuppression.
- On track to file an IND and begin Phase 1 trial for SC451, an iPSC-derived islet cell therapy, as early as 2026.
- Goal to generate initial human data in 2026 for SG293, an in vivo CD19-directed CAR T cell therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526012664/0001193125-26-012664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526012664/sana-20260114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-012664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer